Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

Yoo Mee Kim, Bong Soo Cha, Dae Jung Kim, Sung Hee Choi, Soo Kyung Kim, Chul Woo Ahn, Sungkil Lim, Kyung Rae Kim, Kap Bum Huh, Hyun Chul Lee

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

This study evaluated the efficacy of rosiglitazone in non-obese and obese Korean type 2 diabetic patients of long duration. A total of 125 patients (M:F = 44:81, mean age: 58.4 ± 9.1 years, BMI: 24.2 ± 2.7 kg/m 2, duration of diabetes: 11.0 ± 6.4 years) were randomly allocated to 12 weeks of rosiglitazone treatment (4 mg per day) or a control group. Responders were defined as patients who experienced fasting plasma glucose (FPG) reduction of >20% or HbA1c reduction of >1 (%). Rosiglitazone significantly improved glycemic control by reducing FPG and HbA1c (-3.4 mmol/l and -1.1%, P < 0.001, respectively). It also significantly increased HOMAβ-cell function (+9.7, P < 0.01) and QUICKI (+0.029, P < 0.001), and decreased HOMAIR (-1.73, P < 0.001). Females and those with higher waist-hip ratio made up a greater portion of rosiglitazone-responders. Responders (45 patients, 75%) also showed significantly higher FPG, HbA1c, systolic blood pressures, fasting insulin levels and HOMAIR, and lower QUICKI than nonresponders. Among these parameters of responders, waist-hip ratio of non-obese subgroup, initial glycemic control of obese subgroup, and systolic blood pressure of both subgroups lost their significance after subdivision analysis. However, the baseline HOMAIR and QUICKI were significantly correlated with the response rate to rosiglitazone. Moreover, in multiple logistic regression analysis, HOMAIR and QUICKI retained their significance as the independent predictors. Even in Korean type 2 diabetic patients of long duration but with relatively preserved β-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and β-cell function. In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders.

Original languageEnglish
Pages (from-to)43-52
Number of pages10
JournalDiabetes Research and Clinical Practice
Volume67
Issue number1
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

rosiglitazone
Type 2 Diabetes Mellitus
Fasting
Blood Pressure
Waist-Hip Ratio
Glucose
Therapeutics
Insulin Resistance
Abdominal Obesity
Ethnic Groups

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, Yoo Mee ; Cha, Bong Soo ; Kim, Dae Jung ; Choi, Sung Hee ; Kim, Soo Kyung ; Ahn, Chul Woo ; Lim, Sungkil ; Kim, Kyung Rae ; Huh, Kap Bum ; Lee, Hyun Chul. / Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. In: Diabetes Research and Clinical Practice. 2005 ; Vol. 67, No. 1. pp. 43-52.
@article{cf843ad20b014bc88fc2ebe84bc5eeb1,
title = "Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus",
abstract = "This study evaluated the efficacy of rosiglitazone in non-obese and obese Korean type 2 diabetic patients of long duration. A total of 125 patients (M:F = 44:81, mean age: 58.4 ± 9.1 years, BMI: 24.2 ± 2.7 kg/m 2, duration of diabetes: 11.0 ± 6.4 years) were randomly allocated to 12 weeks of rosiglitazone treatment (4 mg per day) or a control group. Responders were defined as patients who experienced fasting plasma glucose (FPG) reduction of >20{\%} or HbA1c reduction of >1 ({\%}). Rosiglitazone significantly improved glycemic control by reducing FPG and HbA1c (-3.4 mmol/l and -1.1{\%}, P < 0.001, respectively). It also significantly increased HOMAβ-cell function (+9.7, P < 0.01) and QUICKI (+0.029, P < 0.001), and decreased HOMAIR (-1.73, P < 0.001). Females and those with higher waist-hip ratio made up a greater portion of rosiglitazone-responders. Responders (45 patients, 75{\%}) also showed significantly higher FPG, HbA1c, systolic blood pressures, fasting insulin levels and HOMAIR, and lower QUICKI than nonresponders. Among these parameters of responders, waist-hip ratio of non-obese subgroup, initial glycemic control of obese subgroup, and systolic blood pressure of both subgroups lost their significance after subdivision analysis. However, the baseline HOMAIR and QUICKI were significantly correlated with the response rate to rosiglitazone. Moreover, in multiple logistic regression analysis, HOMAIR and QUICKI retained their significance as the independent predictors. Even in Korean type 2 diabetic patients of long duration but with relatively preserved β-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and β-cell function. In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders.",
author = "Kim, {Yoo Mee} and Cha, {Bong Soo} and Kim, {Dae Jung} and Choi, {Sung Hee} and Kim, {Soo Kyung} and Ahn, {Chul Woo} and Sungkil Lim and Kim, {Kyung Rae} and Huh, {Kap Bum} and Lee, {Hyun Chul}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.diabres.2004.05.001",
language = "English",
volume = "67",
pages = "43--52",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. / Kim, Yoo Mee; Cha, Bong Soo; Kim, Dae Jung; Choi, Sung Hee; Kim, Soo Kyung; Ahn, Chul Woo; Lim, Sungkil; Kim, Kyung Rae; Huh, Kap Bum; Lee, Hyun Chul.

In: Diabetes Research and Clinical Practice, Vol. 67, No. 1, 01.01.2005, p. 43-52.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

AU - Kim, Yoo Mee

AU - Cha, Bong Soo

AU - Kim, Dae Jung

AU - Choi, Sung Hee

AU - Kim, Soo Kyung

AU - Ahn, Chul Woo

AU - Lim, Sungkil

AU - Kim, Kyung Rae

AU - Huh, Kap Bum

AU - Lee, Hyun Chul

PY - 2005/1/1

Y1 - 2005/1/1

N2 - This study evaluated the efficacy of rosiglitazone in non-obese and obese Korean type 2 diabetic patients of long duration. A total of 125 patients (M:F = 44:81, mean age: 58.4 ± 9.1 years, BMI: 24.2 ± 2.7 kg/m 2, duration of diabetes: 11.0 ± 6.4 years) were randomly allocated to 12 weeks of rosiglitazone treatment (4 mg per day) or a control group. Responders were defined as patients who experienced fasting plasma glucose (FPG) reduction of >20% or HbA1c reduction of >1 (%). Rosiglitazone significantly improved glycemic control by reducing FPG and HbA1c (-3.4 mmol/l and -1.1%, P < 0.001, respectively). It also significantly increased HOMAβ-cell function (+9.7, P < 0.01) and QUICKI (+0.029, P < 0.001), and decreased HOMAIR (-1.73, P < 0.001). Females and those with higher waist-hip ratio made up a greater portion of rosiglitazone-responders. Responders (45 patients, 75%) also showed significantly higher FPG, HbA1c, systolic blood pressures, fasting insulin levels and HOMAIR, and lower QUICKI than nonresponders. Among these parameters of responders, waist-hip ratio of non-obese subgroup, initial glycemic control of obese subgroup, and systolic blood pressure of both subgroups lost their significance after subdivision analysis. However, the baseline HOMAIR and QUICKI were significantly correlated with the response rate to rosiglitazone. Moreover, in multiple logistic regression analysis, HOMAIR and QUICKI retained their significance as the independent predictors. Even in Korean type 2 diabetic patients of long duration but with relatively preserved β-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and β-cell function. In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders.

AB - This study evaluated the efficacy of rosiglitazone in non-obese and obese Korean type 2 diabetic patients of long duration. A total of 125 patients (M:F = 44:81, mean age: 58.4 ± 9.1 years, BMI: 24.2 ± 2.7 kg/m 2, duration of diabetes: 11.0 ± 6.4 years) were randomly allocated to 12 weeks of rosiglitazone treatment (4 mg per day) or a control group. Responders were defined as patients who experienced fasting plasma glucose (FPG) reduction of >20% or HbA1c reduction of >1 (%). Rosiglitazone significantly improved glycemic control by reducing FPG and HbA1c (-3.4 mmol/l and -1.1%, P < 0.001, respectively). It also significantly increased HOMAβ-cell function (+9.7, P < 0.01) and QUICKI (+0.029, P < 0.001), and decreased HOMAIR (-1.73, P < 0.001). Females and those with higher waist-hip ratio made up a greater portion of rosiglitazone-responders. Responders (45 patients, 75%) also showed significantly higher FPG, HbA1c, systolic blood pressures, fasting insulin levels and HOMAIR, and lower QUICKI than nonresponders. Among these parameters of responders, waist-hip ratio of non-obese subgroup, initial glycemic control of obese subgroup, and systolic blood pressure of both subgroups lost their significance after subdivision analysis. However, the baseline HOMAIR and QUICKI were significantly correlated with the response rate to rosiglitazone. Moreover, in multiple logistic regression analysis, HOMAIR and QUICKI retained their significance as the independent predictors. Even in Korean type 2 diabetic patients of long duration but with relatively preserved β-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and β-cell function. In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders.

UR - http://www.scopus.com/inward/record.url?scp=19944417898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944417898&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2004.05.001

DO - 10.1016/j.diabres.2004.05.001

M3 - Article

VL - 67

SP - 43

EP - 52

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 1

ER -